|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||217.48 - 220.39|
|52 Week Range||175.66 - 248.39|
|PE Ratio (TTM)||171.07|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||3.00 (1.36%)|
|1y Target Est||251.41|
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
CE-IVD labeled PAXgene® Blood ccfDNA tube will be available in Western Europe FRANKLIN LAKES, N.J. and EYSINS, Switzerland , Feb. 20, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), ...
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) Cardiovascular segment registered strong YoY (year-over-year) sales growth of ~8.7% on a reported basis. The segment’s PI (peripheral interventions) division came in at $277 million, registering a YoY rise of 8.4%, whereas the IC (interventional cardiology) division reported sales of $636 million, a YoY rise of ~8.8%. The operational sales growth of BSX’s Cardiovascular segment came in at ~6.8%.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) MedSurg segment witnessed double-digit YoY (year-over-year) growth of ~14.2%, on a reported basis. The segment’s operational sales growth came in at ~12.8%, whereas it grew ~11.2% on an organic basis.
Stock Monitor: ConforMIS Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors.com has just released a free research report on Becton, Dickinson and Co. (NYSE: BDX ) ("BD"). ...
Divestitures Satisfy All Contingencies from Regulatory Authorities Related to Acquisition of C. R. Bard, Inc. FRANKLIN LAKES, N.J. , Feb. 15, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: ...
Becton, Dickinson and Company (BDX) (or BD) announced the completion of its acquisition of Bard on January 29, 2018. The company announced some of the anticipated 2018 launches related to Bard during its fiscal 1Q18 earnings results on February 6, 2018. The chart below shows the 2017 Bard product launches, which are expected to impact BD’s sales.
Medical supplier stocks toppled to a 10-month low on reports Amazon is planning to sell goods to hospitals.
Becton, Dickinson and Company (BDX) (or BD) closed its acquisition of Bard on December 29, 2017. The company had announced the $24 billion acquisition in April 2017. In 2017, BD’s acquisition of Bard is the second-largest M&A (mergers and acquisition) deal after Johnson & Johnson’s (JNJ) $30 billion Actelion acquisition.